Clinical Trials
This is a list of clinical trials and research protocols underway that will help us study thyroid malignancies and other endocrine neoplasias. If you would like to participate in one of the trials, please call the Information Line toll-free at 1-800-392-1611 or askMDAnderson at 1-877-632-6789. For information on other clinical trials, please visit MD Anderson's Clinical Trials website.
Last updated April 17, 2024
- Thyroid Cancer
- Pituitary Tumors
- Other Endocrine Neoplasias including solid tumors
- Other MD Anderson Clinical Trials relevant to Endocrine Neoplasia patients
Thyroid cancer
The goal of this clinical research study is to estimate the median progression-free survival (PFS) from the start of adjuvant pembrolizumab until locoregional progression, development of distant metastatic disease, or death in stage IVB ATC patients with gross disease, treated with external beam radiation (+/- concomitant chemotherapy) followed by adjuvant pembrolizumab
Protocol 2020-0570: Neoadjuvant/Adjuvant Treatment with Selpercatinib in RET-Altered Thyroid Cancers.
The goal of this clinical research study is to learn the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material [deoxyribonucleic acid [DNA]).
Protocol 2019-0770: Lenvatinib in combination with pembrolizumab for stage IVB locally advanced and unresectable or stage IVC metastatic anaplastic thyroid cancer
The goal of this clinical research study is to learn how well Lenvatinib and Pembrolizumab work in treating patients with Anaplastic Thyroid Cancer that is stage IVB and has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable), or stage IVC that has spread to other places in the body (metastasis)
Protocol 2023-0123: A phase I trial of concurrent intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF mutated anaplastic or poorly differentiated Thyroid Cancer
The goal of this clinical research study is to learn how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer.
Protocol 2020-0641: Pembrolizumab in combination with dabrafenib and trametinib as a neoadjuvant strategy prior to surgery in BRAF-mutated anaplastic thyroid cancer
The goal of this clinical research study is to learn the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer.
Protocol 2021-1173: A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer
This goal of this clinical research study is to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC).
Protocol 2023-0365: Targeted therapy to increase RAI uptake in patients with metastatic differentiated thyroid Cancer
The goal of this clinical research study is to evaluate the impact of radioactive iodine (RAI) avidity in patients with metastatic differentiated thyroid cancer.
Other endocrine neoplasias, including solid tumors
Protocol 2017-0948: A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane with Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma with High Risk of Recurrence (ADIUVO-2 Trial)
The goal of this clinical research study is to learn if mitotane alone or in combination with cisplatin and etoposide can help to control adrenocortical carcinoma (ACC) in patients who are at a high risk of having the disease return after surgery.
Protocol 2021-0270: A A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan(MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations
The goal of this clinical research study is to evaluate the efficiency and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET)
The goal of this clinical research study is to evaluate the overall safety and tolerability of 68Ga-R8760 in patients with adrenocortical carcinoma.
Protocol 2022-0705: A Phase 11 Study to evaluate the efficacy and safety of pembrolizumab in combination with mitotane in patients with advanced adrenocortical carcinoma
The goal of this clinical research study is to learn if adding pembrolizumab to mitotane can help control ACC.
Other MD Anderson clinical trials relevant to endocrine neoplasia patients
Protocol 2017-0202: A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of LOXO-292 that can be given to patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer, and any other tumors that have the RET mutation (a type of genetic change). The goal of Part 2 of this clinical research study is to learn if the dose of LOXO-292 found in Part 1 can help to control the disease. The safety of LOXO-292 will also be studied in both parts. This is the first study using LOXO-292 in humans.